Reuters logo
8 个月前
BRIEF-Novan reports statistically significant phase 2 clinical trial results for sb206
2016年11月29日 / 上午11点17分 / 8 个月前

BRIEF-Novan reports statistically significant phase 2 clinical trial results for sb206

1 分钟阅读

Nov 29 (Reuters) - Novan Inc :

* Novan announces statistically significant phase 2 clinical trial results for sb206

* Novan Inc - company plans end-of-phase 2 meeting with fda for first half of 2017

* Novan Inc - plans to initiate company's late-stage program with phase 3 pivotal clinical trials of sb206 in second half of 2017

* Novan - highest dose tested, sb206 12 pct, demonstrated statistically significant improvement in incidence of complete clearance of all baseline warts Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below